| Literature DB >> 34831521 |
Sérgio Francisco de Aquino1, Emanuel Manfred Freire Brandt2, Sue Ellen Costa Bottrel2, Fernanda Bento Rosa Gomes3, Silvana de Queiroz Silva4.
Abstract
The risks of pharmaceuticals and endocrine disrupting compounds (P&EDC) to the environment and human health are a current topic of interest. Hundreds of P&EDC may reach the environment, hence, there is a need to rank the level of concern of human exposure to these compounds. Thus, this work aimed at setting a priority list of P&EDC in Brazil, by studying their occurrence in raw and drinking water, calculating health guideline values (GV), and estimating the risks of population exposure to water intake. Data on the Brazilian pharmaceutical market as well as published data of the monitoring of Brazilian natural and drinking water have been collected by means of an exhaustive literature review. Furthermore, many foreign data were also collected to enable a comparison of the values found in Brazilian studies. A list of 55 P&EDC that have the potential to be found in Brazilian water is proposed, and for 41 of these a risk assessment was performed by estimating their margin of exposure (ME), by considering their occurrence in drinking water, and guideline values estimated from reported acceptable daily intake (ADI) data. For seven compounds the risk was deemed high (three estrogens and four anti-inflammatories), whereas for another seven compounds, it was regarded as an 'alert' situation. Although such risk analysis is conservative, since it has been calculated based on the highest reported P&EDC concentration in drinking water, it highlights the need to enhance their monitoring in Brazil to strengthen the database and support decision makers. An analysis of the occurrence of antimicrobial resistance agents (antibiotics, resistant bacteria, and resistance genes) in surface waters was also carried out and confirmed that such agents are present in water sources throughout Brazil, which deserves the attention of policy makers and health agents to prevent dissemination of antimicrobial resistance through water use.Entities:
Keywords: antibiotics; antimicrobial resistance; contaminants of emerging concern; drinking water; hormones; quantitative chemical risk assessment; resistance genes; resistant bacteria
Mesh:
Substances:
Year: 2021 PMID: 34831521 PMCID: PMC8620687 DOI: 10.3390/ijerph182211765
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Sampling sites of the monitoring studies surveyed to compile data on occurrence of P&EDC compounds in Brazilian natural and drinking water.
Occurrence of pharmaceuticals and endocrine disrupting compounds (P&EDC) in Brazilian and foreign water (…).
| Compound | Matrix | Brazil | Other Countries | ||||
|---|---|---|---|---|---|---|---|
| N | Concentration Range (ng/L) | References | N | Concentration Range (ng/L) | References | ||
| Paracetamol/ | RW | 132 | <0.20–2147.00 | [ | nr | <1.83–43.518 | [ |
| DW | 121 | <0.20–453.60 | [ | nr | <LD a–7.00 | [ | |
| Loratadine 2 | RW | 105 | <1.90–486.00 | [ | nr | <0.03–0.6 | [ |
| DW | 104 | <1.90–67.00 | [ | - | - | - | |
| Promethazine 2 | RW | 23 | <0.30–77.40 | [ | 1 | <0.2 | [ |
| DW | 20 | <0.30–30.84 | [ | - | - | - | |
| Amoxicillin 3 | RW | 74 | <0.46–8.90 | [ | 31 | <LD | [ |
| DW | 72 | <31.50 | [ | 21 | <LD | [ | |
| Cefalexin 3 | RW | 2 | <0.64–29.00 | [ | nr | 283 | [ |
| DW | - | - | - | - | - | - | |
| Ciprofloxacin 3 | RW | 2 | <0.41–2.50 | [ | nr | <LD–1407 | [ |
| DW | - | - | - | 25 | <20 | [ | |
| Clarithromycin 3 | RW | 72 | <63.50 | [ | nr | <1.22–9831.5 | [ |
| DW | 72 | <32.50 | [ | nr | <LD | [ | |
| Enoxacin 3 | RW | 72 | <134.00–386.00 | [ | nr | < 2250 b | [ |
| DW | 72 | <401.60 | [ | - | - | - | |
| Enrofloxacin 3 | RW | 72 | <11.80–71.00 | [ | nr | <LD–142.3 | [ |
| DW | 72 | <5.00–219.00 | [ | - | - | - | |
| Linezolid 3 | RW | 21 | <1.75 | [ | 19 | <LD–87.6 | [ |
| DW | 20 | <1.75–901.20 | [ | - | - | - | |
| Norfloxacin 3 | RW | 74 | <0.40–285.00 | [ | nr | <6.64–261 | [ |
| DW | 72 | <39.30–210.00 | [ | nr | < 20.00 | [ | |
| Sulfamethoxazole 3 | RW | 74 | <0.80–1826.30 | [ | nr | <0.25–1820 | [ |
| DW | 70 | <1.10–2592.60 | [ | nr | <0.25–1.81 | [ | |
| Tetracycline 3 | RW | 2 | <2.50–11.00 | [ | 21 | < LD | [ |
| DW | - | - | - | - | - | - | |
| Trimethoprim 3 | RW | 81 | <0.60–1573.90 | [ | nr | <0.25–176 | [ |
| DW | 78 | <0.60–4381.20 | [ | nr | <14 | [ | |
| Metformin 4 | RW | 138 | <1.39–203.00 | [ | nr | 8.4–3200 | [ |
| DW | 138 | <1.39–111.20 | [ | nr | <LD | [ | |
| Fluconazole 5 | RW | 72 | <7.40–1413.00 | [ | 58 | <0.30–898.8 | [ |
| DW | 72 | <8.70–750.00 | [ | - | - | - | |
| Atenolol 6 | RW | 72 | <20.50 | [ | nr | <0.25–941.1 | [ |
| DW | 72 | <14.50 | [ | nr | <0.25–715.00 | [ | |
| Diltiazem 6 | RW | 21 | <1.22 | [ | nr | <LD–6.9 | [ |
| DW | 20 | <1.22 | [ | - | - | - | |
| Losartan 6 | RW | 66 | <1.00–926.00 | [ | nr | <14.00–620.00 | [ |
| DW | 66 | <1.00–576.40 | [ | nr | <14.00–150.00 | [ | |
| Propanolol 6 | RW | 66 | <8.30–271.20 | [ | 85 | <1.1–537 | [ |
| DW | 66 | <8.30–6837.00 | [ | 26 | <1.1–130 | [ | |
| Atorvastatin 7 | RW | 72 | <80.80–1020.00 | [ | nr | <0.50–530 | [ |
| DW | 72 | <25.30–654.00 | [ | nr | <0.50 | [ | |
| Bezafibrate 7 | RW | 75 | <71.70–1365.00 | [ | nr | <1.8–256.7 | [ |
| DW | 71 | <2.90–1659.10 | [ | nr | <LD–0.16 | [ | |
| Gemfibrozil 7 | RW | 202 | <0.30–2032.00 | [ | nr | <0.25–210 | [ |
| DW | 193 | <0.30–2253.00 | [ | nr | <0.25–300 | [ | |
| Triclosan 8 | RW | 20 | <0.70–66.00 | [ | nr | <1.0–102 | [ |
| DW | 100 | <3.00 | [ | nr | <1.0–1.93 | [ | |
| Cimetidine 9 | RW | 74 | 2.60–13.90 | [ | 1 | <1.8 | [ |
| DW | 72 | <29.60 | [ | - | - | - | |
| Omeprazole 9 | RW | 72 | <32.00 | [ | nr | <2.96 | [ |
| DW | 72 | <17.80 | [ | 21 | <LD a | [ | |
| Ranitidine 9 | RW | 74 | 8.30–15.80 | [ | nr | <5.0–498 | [ |
| DW | 72 | <26.70 | [ | - | - | - | |
| Acyclovir 10 | RW | 21 | <0.95–220.40 | [ | 9 | <10 | [ |
| DW | 20 | <0.95–93.08 | [ | 5 | <10 | [ | |
| Bisphenol A 11 | RW | 166 | <0.03–64,831.00 | [ | nr | <0.99–763 | [ |
| DW | 227 | <0.03–2549.10 | [ | nr | <0.99–683 | [ | |
| 4-Nonylphenol 11 | RW | 145 | <0.10–1918.00 | [ | 56 | <2.05–130.00 | [ |
| DW | 224 | <0.10–2820.00 | [ | 27 | <2.05–16 | [ | |
| 4-Octylphenol 11 | RW | 134 | <0.10–835.10 | [ | nr | <0.66 | [ |
| DW | 123 | <0.20–276.60 | [ | nr | <0.66 | [ | |
| 17-beta-Estradiol 12 | RW | 146 | <0.25–6806.00 | [ | nr | <0.81–4.04 | [ |
| DW | 123 | <0.25–43.50 | [ | nr | <0.81 | [ | |
| Estriol 12 | RW | 138 | <0.08–67.40 | [ | 36 | <4.70–72.00 | [ |
| DW | 221 | <0.08–97.40 | [ | 36 | <4.70 | [ | |
| Estrone 12 | RW | 143 | <0.07–279.50 | [ | nr | <0.20–130 | [ |
| DW | 223 | <0.07–94.80 | [ | nr | <0.92 | [ | |
| 17-alpha- | RW | 153 | <0.39–4390.00 | [ | nr | <0.20–3.40 | [ |
| DW | 223 | <0.39–623.00 | [ | nr | <2.66 | [ | |
| Levonorgestrel 13 | RW | 9 | <1.00–663.00 | [ | 39 | <0.42 | [ |
| DW | 100 | <1.00 | [ | 11 | <0.05–0.7 | [ | |
| Acetylsalicylic acid 14 | RW | 12 | <0.041–15,687.90 | [ | nr | <LD–1130 | [ |
| DW | 6 | <0.04–5286.90 | [ | nr | <LD | [ | |
| Diclofenac 14 | RW | 72 | <0.28–723.20 | [ | nr | <0.25–10,200 | [ |
| DW | 59 | <0.28–1405.00 | [ | nr | <0.25–2.37 | [ | |
| Ibuprofen 14 | RW | 205 | 0.02–4155.50 | [ | nr | <1.96–17,600 | [ |
| DW | 195 | <0.28–490.20 | [ | nr | <18.00 | [ | |
| Ketoprofen 14 | RW | 72 | <34.70–1020.00 | [ | nr | <LD–9220 | [ |
| DW | 72 | <64.60–561.00 | [ | nr | <LD–40 | [ | |
| Naproxen 14 | RW | 64 | <0.20–22,408.00 | [ | nr | <0.50–59,300 | [ |
| DW | 53 | <0.20–372.632.00 | [ | nr | <LD–3.12 | [ | |
| Betamethasone 15 | RW | 72 | <8.00–11,960.00 | [ | 17 | 0.29–7.2 | [ |
| DW | 72 | <8.00–2620.00 | [ | 11 | <0.02–1.0 | [ | |
| Dexamethasone 15 | RW | 79 | <2.86–2159.00 | [ | nr | <LD–9.7 | [ |
| DW | 78 | <2.86–2271.00 | [ | nr | <0.02–< 0.05 | [ | |
| Prednisone 15 | RW | 72 | <5.10–8105.00 | [ | nr | <0.02–1.3 | [ |
| DW | 72 | <4.8–6323.00 | [ | nr | <0.03–0.05 | [ | |
N: amount of data; RW: raw water (water source that feeds a WTP); DW: drinking water (water distributed by a WTP); nr: not reported in the original paper; LD: limit of detection; a: data not reported; b: maximum. 1: analgesic/antipyretic; 2: antiallergic; 3: antibiotic; 4: antidiabetic; 5: antifungal; 6: antihypertensive; 7: antilipemic; 8: antiseptic; 9: antiulcer; 10: antiviral; 11: chemical input; 12: estrogen; 13: hormonal contraceptive; 14: nonsteroidal anti-inflammatory; 15: steroidal anti-inflammatory. Raw data can be found in Tables S2 and S3.
Pharmaceuticals and endocrine disrupting compounds (P&EDC) selected for further risk assessment.
| Compound | Reason for Selection | Compound | Reason for Selection | ||
|---|---|---|---|---|---|
| Occurrence in Brazilian Water | Top-Selling in Brazil | Occurrence in Brazilian Water | Top-Selling in Brazil | ||
| Acyclovir | x | Gemfibrozil | x | ||
| Acetylsalicylic acid | x | Hydrochlorothiazide | x | ||
| Albendazole | x | Ibuprofen | x | x | |
| Amoxicillin | x | Ketoprofen | x | ||
| Atenolol | x | Levonorgestrel | x | x | |
| Atorvastatin | x | Levothyroxine | x | ||
| Azithromycin | x | Linezolid | x | ||
| Amlodipine besilate | x | Loratadine | x | ||
| Betamethasone | x | Losartan | x | x | |
| Bezafibrate | x | Metformin | x | x | |
| Bisphenol A | x | Naproxen | x | ||
| Cefalexin | x | x | Nimesulide | x | |
| Cimetidine | x | Nonylphenol | x | ||
| Ciprofloxacin | x | Norfloxacin | x | ||
| Clarithromycin | x | Octylphenol | x | ||
| Clonazepam | x | Omeprazole | x | ||
| Dexamethasone | x | Paracetamol | x | x | |
| Diclofenac | x | x | Prednisone | x | |
| Diltiazem | x | Promethazine | x | ||
| Dipyrone | x | Propanolol | x | ||
| Enalapril | x | Ranitidine | x | ||
| Enoxacin | x | Sildenafil | x | ||
| Enrofloxacin | x | Simvastatin | x | ||
| 17- beta-Estradiol | x | Sulfamethoxazole | x | x | |
| Estriol | x | Tetracycline | x | x | |
| Estrone | x | Triclosan | x | ||
| 17-alpha-Ethinylestradiol | x | x | Trimethoprim | x | x |
| Fluconazole | x | ||||
Toxicity ranking of pharmaceuticals and endocrine disrupting compounds (P&EDC) based on the lowest calculated values of acceptable daily intake (ADI) in comparison to the guideline value (GV).
| Compound | ADI | GV | Compound | ADI | GV | ||
|---|---|---|---|---|---|---|---|
| 1° | 17-alpha-Ethinylestradiol | 0.0001–0.005 | 0.003 a–0.15 | 29° | Trimethoprim | 1.7–191 | 5.0–575 |
| 2° | Levothyroxine | 0.0002 | 0.006 | 30° | Diltiazem | 2.0 | 60 |
| 3° | 17- beta-Estradiol | 0.0003 b–0.05 | 0.008–0.30 | 31° | Azithromycin | 3.0–8.3 | 9.0–25 |
| 4° | Levonorgestrel | 0.0005 | 0.015 | 32° | Cimetidine | 3.3 | 100 |
| 5° | Dexamethasone | 0.008 | 0.025–0.045 | 33° | Nimesulide | 3.3 | 100 |
| 6° | Betamethasone | 0.008 | 0.25 | 34° | Bisphenol A | 4.0–50 | 72–900 |
| 7° | Clonazepam | 0.008 | 0.25 | 35° | Paracetamol | 5.4–50 | 160–1500 |
| 8° | Estrone | 0.013–0.05 | 0.078 a–0.30 | 36° | Enrofloxacin | 6.2 | 20 |
| 9° | Enalapril | 0.04–0.23 | 1.3–7.0 | 37° | Enoxacin | 6.7 | 200 |
| 10° | Prednisone | 0.042 | 0.13 | 38° | Albendazole | 6.7 | 20 |
| 11° | Estriol | 0.05 | 0.01–0.30 | 39° | Acetylsalicylic acid | 7.2 | 22 |
| 12° | Amlodipine besilate | 0.08 | 2.5 | 40° | Naproxen | 7.3 | 220 |
| 13° | Simvastatin | 0.08–0.7 | 2.5–20 | 41° | Metformin | 8.3 | 250 |
| 14° | Loratadine | 0.17 | 5.0 | 42° | Clarithromycin | 8.3 | 250 |
| 15° | Atorvastatin | 0.17–6.7 | 5.0–200 | 43° | Dipyrone | 8.3–150 | 25–450 |
| 16° | Omeprazole | 0.17 | 5.0 | 44° | Sulfamethoxazole | 10–512 | 30–1535 |
| 17° | Hydrochlorothiazide | 0.21 | 0.6 | 45° | Bezafibrate | 10 | 300 |
| 18° | Sildenafil | 0.21 | 6.3 | 46° | Cefalexin | 10 | 30 |
| 19° | Promethazine | 0.33 | 10 | 47° | Acyclovir | 13.3 | 400 |
| 20° | Losartan | 0.42 | 13 | 48° | Ibuprofen | 13.3 | 400 |
| 21° | Diclofenac | 0.5–67 | 1.5–200 | 49° | Linezolid | 13.3 | 400 |
| 22° | Propanolol | 0.5 | 15 | 50° | Norfloxacin | 13.3 | 40 |
| 23° | Amoxicillin | 0.5 | 1.5 | 51° | Octylphenol | 15 | 90 |
| 24° | Fluconazole | 0.8 | 25 | 52° | Nonylphenol | 15–50 | 90–300 |
| 25° | Atenolol | 0.8–2,7 | 25–80 | 53° | Gemfibrozil | 20–31 | 600–930 |
| 26° | Ketoprofen | 1.0–1.7 | 3.0–5.0 | 54° | Tetracycline | 30 | 90 |
| 27° | Ranitidine | 1.3 | 38 | 55° | Triclosan | 50–75 | 150–225 |
| 28° | Ciprofloxacin | 1.6–83 | 4.8–25 |
a: For the case of 17-alpha-ethinylestradiol, 17-beta-estradiol, and estrone, the lowest therapeutic daily dose was not used to estimate the GV; b: Considering carcinogenic effects.
Figure 2Concentration range, guideline values, and margin of exposure of pharmaceutical and endocrine disrupting compounds (P&EDC) quantified in Brazilian drinking water, which exhibited high risk. EE2 = 17-alpha-ethinylestradiol; E2 = 17-beta-estradiol; E1 = Estrone; DEX = Dexamethasone; PRE = Prednisone; BET = Betamethasone; NPX = Naproxen.
Reported occurrence of resistant bacteria (ARB) and resistance genes (ARG) in Brazilian surface waters (to be continued).
| Target | Location | Phenotypic Antibiotic Resistance (AR) | Genetic Elements | Reference |
|---|---|---|---|---|
|
| Surface water in agricultural area, Rio de Janeiro (RJ) | 57.7% of isolates were resistant at least to one of the 11 antimicrobials tested: AMI, AMP, CFL, CPM, CFO, CIP, GEN, NIT, NOR, SUT, TRI. | nd | [ |
| Surface water in recreational area, Rio de Janeiro (RJ) | 56.4% of isolates were resistant at least to one of the 11 antimicrobials tested: AMI, AMP, CFL, CPM, CFO, CIP, GEN, NIT, NOR, SUT, TRI. | nd | [ | |
| Patos Lagoon (RS) | 35% of isolates were resistant at least to one of the 17 antimicrobials tested: AMP, CFO, CPM, AMI, GEN, NOR, AMX/CLA, PIP/TZB, ATM, IPM, CAZ, CFT, CLO, TET, TRI/SMX, SUL, STM, SPM. | qacEΔ1, dfrA1, dfrA12, dfrA17, aadA1, aadA5, aadA22. | [ | |
| Belém and Barigui | 33% of isolates were resistant to AMX, 28% to SMX, 10% to NOR, 13% to CIP, 3% to DOX. | nd | [ | |
| Fecal coliforms | Drinking and surface water in Morrinhos (GO) | 14.6% of the isolates were resistant to AMP, 7.9% to TET, 3.4% to CIP. | Stable plasmids | [ |
|
| Dilúvio River, Porto Alegre (RS) | 37.50% of the isolates were resistant to ERI, 27.27% to PEN, 12.50% to CLI, 6.81% to TRI/SMX, 5.68% to CLO, 2.27% to NOR. | nd | [ |
| Belém and Barigui | 4% of isolates were resistant to CIP, 2% to NOR, 1.7% to VAN, none were resistant to AMX. | nd | [ | |
| Rivers from Apucarana City, (PR) | One isolate was resistant to TET; any isolate was resistant to AMP, CIP, ERT, GEN, NOR, TET, VAN. | nd | [ | |
|
| Belém and Barigui | No resistance was observed among isolates. | nd | [ |
| Rivers, streams, and lakes from São Paulo | 87% of the isolates were resistant to TET, 78% to CET, 78% to CFT, 74% to CLO, 62% to PIP/TZB, 61% to CAZ, 52% to ATM, 30% to CIP, 30% to LEV, 30% to NOR, 26% to CPM, 13% to IPM, 13% to MER, 9% to GEN and 9% to TBM. | blaGES, qnrS, qepA, tetB, aac(3′)-IIa, and ant(2″)-Ia, no plasmids were found. | [ | |
|
| Mineral water, tap water, artesian water | 91% of the isolates were resistant to AMP, 87% to CFL, 52% to CLO, 30% to CFT, 30% to ATM, 26% to GEN, 26% to TET, 26% to TMP/SMX, 17% to NAL and 4% to MER. | nd | [ |
| Cefotazime | Bolonha | 94.9% of isolates were resistant to three or more classes of antibiotics: 96.2% to ATM, 94.3% to CFT, 90.5% to AMX, 88.6% to AMP, 86.7% to NAL, 75.4% to CFL, 75.4% to CA and 71.6% to AMX/CLA. | blaCTX (28.3%), blaSHV (22.6%), blaTEM (18.8%), | [ |
| Imipenen | Bolonha | 85.7% of isolates were resistant to three or more classes of antibiotics: 88.5% to AMX, 80.3% to ATM, 73.7% to AMP, 63.9% to IPM, 62.3% to CFL, 48% to KAN, 47.6% to NAL and 45.9% to CAZ. | blaVIM (28.8%), | [ |
| Ampicillin resistant bacteria (heterotrophs) | Parnaioca river, Rio de Janeiro | No ampicillin resistant bacteria were isolated from this site. | nd | [ |
| Antibiotic resistance genes | Dilúvio River, Porto Alegre (RS) | nd | SulI: 101–104 gene copies/mL; | [ |
| Uberabinha River, | nd | sul2, tetW, ermF | [ |
1 Unless described, all isolates were obtained in growth media without a selective pressure of antibiotic; nd—not determined. Name abbreviations (antibiotic/gene): amikacin (AMI), aminoglycosides (aac(3′)-IIa, ant(2″)-Ia) amoxicillin (AMX), ampicillin (AMP), aztreonam (ATM), β-lactams (blaTEM, blaIMP4, blaGES and blaNDM1), cephalothin (CFL), cefepime (CPM), cefotaxime (CFT), cefoxitin (CFO), ceftazidime (CAZ), ceftriaxone (CET), ciprofloxacin (CIP), clavulanic acid (CLA), clindamycin (CLI), chloramphenicol (CLO), doxycycline (DOX), erythromycin (ERI), gentamicin (GEN), imipenem (IPM), integrons (intI1, intI2), kanamycin (KAN), levofloxacin (LEV), macrolides (ermB), meropenem (MER), nalidixic acid (NAL), nitrofurantoin (NIT), norfloxacin (NOR), penicillin (PEN), piperacillin (PIP), quinolones (qnrS, qepA, gyrA), sulfamethoxazole (SMX), sulfonamides (SUL/sulI), sulphazothrin (SUT), spectinomycin (SPM), streptomycin (STM), tazobactam (TZB), tetracyclines (TET/tetA, tetB, tetC, tetM, tetW), tobramycin (TBM), trimethoprim (TRI), and vancomycin (VAN).
Risk estimation of antimicrobial resistance induction by antibiotics found in Brazilian surface waters.
| PNEC (μg/L) 1 | PNEC (ng/L) | Occurrence in Raw (Surface) Water (ng/L) 2 | MEC (ng/L) | RQ 3 | Risk Classification | |
|---|---|---|---|---|---|---|
| Amoxicillin | 0.25 | 250 | <0.46–8.9 | 8.9 | 0.03 | Low |
| Cefaloxin | 4 | 4000 | <0.64–29 | 29 | 0.007 | Low |
| Ciprofloxacin | 0.064 | 64 | <0.4–2.5 | 2.5 | 0.04 | Low |
| Clarithromycin | 0.25 | 250 | <63.5 | 63.5 | 0.25 | Moderate |
| Enoxacin | NA | NA | <134–386 | 386 | NA | NA |
| Enrofloxacin | 0.064 | 64 | <11.8–71 | 71 | 1.11 | High |
| Linezolide | 8 | 8000 | <1.75 | 1.75 | 0.0002 | Low |
| Norfloxacin | 0.5 | 500 | <0.40–285 | 285 | 0.57 | Moderate |
| Sulfamethoxazole | 16 | <0.8–1826.3 | 1826.3 | 0.11 | Moderate | |
| Tetracycline | 1 | 1000 | <2.5–11 | 11 | 0.01 | Low |
| Trimethoprim | 0.5 | 500 | <0.6–1573.9 | 1573.9 | 3.15 | High |
PNEC: predicted no effect concentration of antibiotics regarding resistance selection; MEC: maximum environmental concentration; RQ: risk quotient; NA—not available; 1 As reported by Bengtsson-Palme and Larsson [63]; 2 As reported in Table 1; 3 According to Equation (5).